Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL. Hu G, et al. Among authors: li y. Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309. Epub 2017 Oct 13. Leukemia. 2018. PMID: 29026208 Free PMC article. No abstract available.
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.
Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Pieter Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC. Amin SB, et al. Among authors: li c, li y. Leukemia. 2014 Nov;28(11):2229-34. doi: 10.1038/leu.2014.140. Epub 2014 Apr 15. Leukemia. 2014. PMID: 24732597 Free PMC article.
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. Wang L, et al. Among authors: li y. Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689. Ann Oncol. 2018. PMID: 29069303 Free PMC article. Clinical Trial.
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Richardson PG, et al. Among authors: li y. Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2. Leukemia. 2017. PMID: 28642620 Free PMC article. Clinical Trial.
PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.
Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S, McCaw L, Wong K, Gary-Gouy H, Dalloul A, Ceddia R, Gorzcynski R. Spaner DE, et al. Among authors: li y. Leukemia. 2013 Apr;27(5):1090-9. doi: 10.1038/leu.2012.329. Epub 2012 Nov 19. Leukemia. 2013. PMID: 23160450
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Richardson PG, et al. Among authors: li y. Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5. Leukemia. 2018. PMID: 30218008 Free PMC article.
240,399 results
You have reached the last available page of results. Please see the User Guide for more information.